Nav: Home

Scientists find three subgroups in a children's brain cancer, identify druggable targets

December 12, 2016

(TORONTO, Canada - Dec. 12, 2016) - Multi-institutional researchers investigating an incurable brain cancer in children have discovered three distinct subgroups of disease and identified promising drugs to target each type.

The research findings are published online today and depicted on the cover of Cancer Cell. Co-principal investigator Dr. Daniel De Carvalho, Scientist at Princess Margaret Cancer Centre, says being able to segregate and classify specific subgroups opens the door to providing precision medicine for children who have a highly malignant, non-inherited type of brain cancer called atypical teratoid rhabdoid tumours (ATRTs).

"Now we have the ability to match the patient to new drugs using this subgroup classification," he says. The next step will be moving into clinical trials to determine if the tumour targets will respond to the drugs, which are already either approved for use or being tested in clinical trials to treat other types of cancer.

Dr. De Carvalho holds the Canada Research Chair in Cancer Epigenetics and Epigenetic Therapy and is an Assistant Professor in Cancer Epigenetics, Department of Medical Biophysics, University of Toronto. In Toronto, the team was co-led by Drs. De Carvalho, James Rutka and Annie Huang, Hospital for Sick Children; and in Montreal, by Nada Jabado, McGill University.

The researchers integrated the analysis of 191 tumour samples provided by international collaborators and 10 cell lines to define the genomic and epigenomic landscape of ATRTs.

The team also discovered that one of the subgroups exhibits distinct sensitivity to two particular drugs that inhibit cell signalling.

Dr. De Carvalho, an epigeneticist whose research focuses on variants in acquired mutations outside the genes, says the analysis showed the subgroups are defined by epigenetic changes and that the cancer is driven by a mutation in epigenetic enzymes.

"The mutation is random, but once it occurs we now know what caused it and, depending on where it occurs, the targets downstream are different."

He says the next research focus will be to learn more about the mechanism of how these subgroups are sensitive to the drugs. "By understanding the mechanism, we can develop new drugs, new targets and new approaches to treatment."
-end-
The research was funded by Genome Canada; b.r.a.i.n.child; Mitchell Duckman, Tal Doron, and Suri Boon foundations; C17 Childhood Cancer and Blood Disorders Research Network; Coast to Coast against Cancer Foundation; Kids with Cancer Society; McGill University and Genome Quebec Innovation Centre; the Princess Margaret Genomics Centre; the Centre for Applied Genomics, Toronto, and The Princess Margaret Cancer Foundation.

About Princess Margaret Cancer Centre, University Health Network

The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to http://www.theprincessmargaret.ca or http://www.uhn.ca .

University Health Network

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...